Drug intelligence / Profile preview

GVX-002

Development stage: Unknown
Lead developer: Glycovax Pharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GVX-002 is a glycoconjugate vaccine candidate developed by Glycovax Pharma for the prevention of COVID-19. The vaccine utilizes a proprietary platform that conjugates synthetic carbohydrate antigens, designed to mimic the glycan structures of the SARS-CoV-2 spike protein, to a carrier protein. This glycoconjugation approach is intended to enhance the immunogenicity and stability of the vaccine, potentially offering a robust defense against the virus. As of early 2025, GVX-002 is in Phase 1 clinical trials.

Other names: Vaccin GVX-002

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on GVX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GVX-002.

Explore the full profile